MedImmune, the Gaithersburg research arm of pharmaceutical giant AstraZeneca, is making aggressive moves to expand its footprint in China.
The company said Wednesday it plans to spend $50 million on another production facility in Wuxi, a city near Shanghai on China’s east coast. The company also announced an expansion to a key manufacturing partnership with a Chinese company, WuXi AppTec.
{iframe}https://www.washingtonpost.com/business/capitalbusiness/medimmune-deepens-its-footprint-in-china-with-new-deal/2015/12/16/8ae908aa-a43e-11e5-9c4e-be37f66848bb_story.html{/iframe}